All In Biotech

NDA 210854 · Genentech INC

Xofluza

Baloxavir Marboxil · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: May 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Oct 24, 2018

Approved uses

9

Original approval plus efficacy supplements

Registered trials

21

14 Phase 3, 7 recruiting

FAERS reports

2,319

1,231 serious, 136 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 24, 2026.

XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for: Treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications . ( 1.1 ) Post-exposure prophylaxis of influenza in patients 5 years of age and older following contact with an individual who has influenza. ( 1.2 ) Limitations of Use Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA. ( 1.3 ) 1.1 Treatment of Influenza XOFLUZA is indicated for treatment of acute uncomplicated influenza in patients 5 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications 1 [see Clinical Studies (14.1 , 14.2 , and 14.3 ]. 1.2 Post-Exposure Prophylaxis of Influenza XOFLUZA is indicated for post-exposure prophylaxis of influenza in persons 5 years of age and older following contact with an individual who has influenza [see Clinical Studies (14.4) ]. 1.3 Limitations of Use Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA [see Warnings and Precautions (5.2) , Microbiology (12.4)...

Mechanism: Baloxavir marboxil is an antiviral drug with activity against influenza virus [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • XOFLUZA · BALOXAVIR MARBOXIL 40MG · TABLET, ORAL · Prescription · TE AB
  • XOFLUZA · BALOXAVIR MARBOXIL 80MG · TABLET, ORAL · Prescription · TE AB
  • XOFLUZA · BALOXAVIR MARBOXIL 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Baloxavir Marboxil" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event547
  • off label use427
  • intentional product use issue283
  • diarrhoea136
  • vomiting132
  • pneumonia115
  • drug ineffective90
  • nausea75
  • rash70
  • hyperpyrexia68
  • headache64
  • influenza60

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
201824
2019814
2020652
202156
202284
2023161
2024123
2025250
2026154

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xofluza (Baloxavir Marboxil)

2024 spending

$1.2M

Beneficiaries

7,548

7,723 claims

Per beneficiary

$166

$158.92 per unit

View as table
YearSpending
2020$1,871,274
2021$644,817
2022$2,414,068
2023$1,027,972
2024$1,249,680

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 33 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.